罗氏Roche Holdings（RHHBY）2012年年度报告「OTC」.pdf

1、Annual Report20122011Key Figures 20121 CER:Constant exchange rates(average full-year 2011).2 Proposed by the Board of Directors.3 Prices translated at constant CHF exchange rates:USD=0.90;EUR=1.20;100 JPY=1.10;GBP=1.40.4 Full-time equivalents.DecMarJunSepDecRoche GS,Price=184.00Roche B,Price=186.90

2、Peer Set Index951051001101151201259045,49915,389+4%+10%17,1608,475+11%+2%13.627.35+10%+8%millions of CHFmillions of CHF(CER)1(CER)millions of CHFmillions of CHF(CER)(CER)CHFCHF(CER)(CER)Group salesCore operating profitOperating free cash flowCore earnings per shareR&D investmentDividend 2326,64282,0

3、89+10.4%+2.4%patientsemployeesNumber of employees 4Patients on clinical trials121117118Total Shareholder Return 2012The value of CHF 100 3 invested 1/1/2012,for the period ending 31/12/20123%Daniel ODayRoland DiggelmannRoche GroupKey Events 2012PharmaceuticalsAt the Roche Annual General Meeting in 2

4、012,shareholders authorised a 3%dividend increase to CHF6.80per share and non-voting equity.It was the companys 25 th dividend increase in as many years.Roche continued to streamline its research and development activities,taking the decision to close its site in Nutley,New Jersey,USA.The respective

5、 R&D activities are being consolidated in Switzerland and Germany.Management changes:Daniel ODay,former Head of Roche Diagnostics,was appointed the new Head of Roche Pharma.Roland Diggelmann has assumed the position of Head of Roche Diagnostics.Our latestage pipeline made considerable progress in 20

6、12,with 11 out of 14 clini-cal trials delivering positive results,underpinning the strength of our innovation strategy.The FDA approved Erivedge(vismodegib),a first-in-class Hedgehog Pathway Inhibitor for adults with advanced basal cell carcinoma.New data from the Phase III EMILIA study showed that